A Study to Measure the Amount of Evacetrapib That Enters the Blood Stream in Healthy Participants
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02271425|
Recruitment Status : Completed
First Posted : October 22, 2014
Last Update Posted : December 18, 2014
Evacetrapib (study drug) is an investigational drug being developed with the aim to help people at high risk of heart problems in the future.
In this study we will be comparing how much of the study drug gets into the blood stream when it is given as a single dose (in tablet form) compared to an intravenous injection (given directly into a vein via a small needle).
The study is expected to last at least 15 days for each participant, not including screening. Screening will occur up to 28 days before the study drug is given.
|Condition or disease||Intervention/treatment||Phase|
|Healthy Volunteers||Drug: Evacetrapib Tablet Drug: Evacetrapib Intravenous||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||8 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||An Absolute Bioavailability Study of Evacetrapib in Healthy Subjects Using the Intravenous Tracer Method|
|Study Start Date :||October 2014|
|Actual Primary Completion Date :||November 2014|
|Actual Study Completion Date :||November 2014|
Experimental: Evacetrapib: Tablet
A single oral dose of evacetrapib tablet
Drug: Evacetrapib Tablet
Other Name: LY2484595
Experimental: Evacetrapib: Intravenous
A single intravenous (IV) dose of evacetrapib administered over a 4 hour infusion.
Drug: Evacetrapib Intravenous
Other Name: LY2484595
- Pharmacokinetics: Area Under the Concentration Versus Time Curve from Zero to Infinity (AUC[0-∞]) of Evacetrapib [ Time Frame: Pre-dose through 168 hours post-dose ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02271425
|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.|
|Leeds, West Yorkshire, United Kingdom, LS2 9LH|
|Study Director:||Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)||Eli Lilly and Company|